NO- and haem-independent soluble guanylate cyclase activators.
about
Kynurenine is an endothelium-derived relaxing factor produced during inflammationExploiting the Pleiotropic Antioxidant Effects of Established Drugs in Cardiovascular DiseaseStructure of cinaciguat (BAY 58-2667) bound to Nostoc H-NOX domain reveals insights into heme-mimetic activation of the soluble guanylyl cyclase.Insights into Soluble Guanylyl Cyclase Activation Derived from Improved Heme-MimeticsFluorescence dequenching makes haem-free soluble guanylate cyclase detectable in living cellsChronic Activation of Heme Free Guanylate Cyclase Leads to Renal Protection in Dahl Salt-Sensitive Rats.Fluorescent fusion proteins of soluble guanylyl cyclase indicate proximity of the heme nitric oxide domain and catalytic domain.Endothelium-derived vasoactive factors and hypertension: possible roles in pathogenesis and as treatment targets.The fibrate gemfibrozil is a NO- and haem-independent activator of soluble guanylyl cyclase: in vitro studies.Reactive oxygen species and small-conductance calcium-dependent potassium channels are key mediators of inflammation-induced hypotension and shockTargeting soluble guanylate cyclase for the treatment of pulmonary hypertension.The anti-aggregating effect of BAY 41-2272, a stimulator of soluble guanylyl cyclase, requires the presence of nitric oxide.Alternative splicing impairs soluble guanylyl cyclase function in aortic aneurysmPulmonary and systemic vasodilator responses to the soluble guanylyl cyclase activator, BAY 60-2770, are not dependent on endogenous nitric oxide or reduced heme.New perspectives for the treatment of pulmonary hypertensionThe soluble guanylate cyclase activator BAY 58-2667 protects against morbidity and mortality in endotoxic shock by recoupling organ systemsCyclic nucleotide signalling in kidney fibrosis.The future is today: emerging drugs for the treatment of erectile dysfunctionCobinamides are novel coactivators of nitric oxide receptor that target soluble guanylyl cyclase catalytic domain.The matricellular protein thrombospondin-1 globally regulates cardiovascular function and responses to stress via CD47.Cinaciguat, a novel activator of soluble guanylate cyclase, protects against ischemia/reperfusion injury: role of hydrogen sulfide.Nitric Oxide Resistance Reduces Arteriovenous Fistula Maturation in Chronic Kidney Disease in RatsSoluble guanylyl cyclase requires heat shock protein 90 for heme insertion during maturation of the NO-active enzyme.Protoporphyrin IX/Cobyrinate Derived Hybrids - Novel Activators of Soluble Guanylyl CyclaseThe Soluble Guanylate Cyclase Stimulator IWP-953 Increases Conventional Outflow Facility in Mouse Eyes.The sGC activator BAY 60-2770 has potent erectile activity in the rat.Cinaciguat prevents the development of pathologic hypertrophy in a rat model of left ventricular pressure overload.A Review of the Pathophysiology and Novel Treatments for Erectile Dysfunction.Pediatric pulmonary arterial hypertension: current and emerging therapeutic options.Nitric oxide: orchestrator of endothelium-dependent responses.Stimulators and activators of soluble guanylate cyclase: review and potential therapeutic indications.Modulation of soluble guanylate cyclase for the treatment of erectile dysfunction.The chemistry and biology of soluble guanylate cyclase stimulators and activators.Redox signaling as a therapeutic target to inhibit myofibroblast activation in degenerative fibrotic diseaseIdentification of downstream target genes regulated by the nitric oxide-soluble guanylate cyclase-cyclic guanosine monophosphate signal pathway in pulmonary hypertension.Regulation of sGC via hsp90, Cellular Heme, sGC Agonists, and NO: New Pathways and Clinical Perspectives.Contemporary Approaches to Modulating the Nitric Oxide-cGMP Pathway in Cardiovascular Disease.Synthesis of New Hydrophilic and Hydrophobic Cobinamides as NO-Independent sGC Activators.Distinct molecular requirements for activation or stabilization of soluble guanylyl cyclase upon haem oxidation-induced degradation.Vitamin B₁₂ derivatives as activators of soluble guanylyl cyclase.
P2860
Q24630488-0DC5FB3B-FDDC-416F-B3A0-FE3A02E2D48BQ26801173-C519D88C-9586-40D9-88EF-1526B92D6809Q27661554-6C1460C1-EB83-46C3-85E7-6D26507334E0Q27680135-D7F0BE2B-A358-40C3-8ADB-426B1B0BB3C7Q28741339-838D1B88-3388-481F-A1C8-498B71A6E226Q30315850-D5563CEC-645A-499E-BEA6-3FF2DDA2BD57Q33640041-4CA54EA3-DB1E-40B9-B781-A5687D4C38CFQ34023606-07A33402-F869-48CB-821C-D3B983BC817FQ34042836-2231B68B-BC23-4475-BF44-C531BFB223A8Q34063569-7103DDF5-F231-4B26-8BE8-22571CD550F7Q34179857-1593F143-C238-4B3D-AFE7-F5701A9D4CDFQ34389020-A30B444A-6CAA-4FBF-BE0B-ECA2F8B86A2EQ34627792-F4F6950C-F0E7-4079-AA1C-C77B678365D6Q34720361-EC8A2EEB-D23F-4D0C-AA1C-0ADE2475A218Q34903204-F99036C0-8E5A-4A42-83DE-9229BC771A38Q34981386-3863ED60-B760-45DC-AF3C-06D847EF189DQ35138860-F6452DB8-933D-4E90-BDE9-BED65BC45BB9Q35186022-C48712EB-8C74-4241-B50B-650178923581Q35776824-62E6D687-2829-4587-99CE-0850598ECF6FQ35809576-FECE5B28-EAB7-46DB-A6D6-E9EBC75FA9A9Q35850118-1DC2D4FD-90F5-4AD6-A96A-62F5D7DA22BCQ35884072-23D07FE0-7DCB-4041-ACCB-2AB57CE74C88Q36167665-DA501B35-143A-4716-93BF-18D6274F620FQ36693586-D8F4FEDD-DEAB-4597-831C-AC44A26367FDQ36738013-E6260F8D-17B0-45C0-A053-8DFD7E336E00Q36923923-142377A3-9550-4241-AA13-F14946A21507Q37419185-9C9602C8-CC09-46A1-AD7B-B77FEF01798CQ37820206-C12A8CD0-7D90-4706-9AF2-D7E27E7BCD5EQ37879213-AE7B0A9B-C964-40DF-889F-D89443FC8476Q37927098-9894C126-17B7-4886-AFC6-D58BA9147881Q38000562-1D1F5F14-B330-45C5-8A7D-45183DA94F6DQ38118626-875ED809-E60C-437A-9E08-A301FAF9F6F8Q38130465-854E8687-6B43-40EF-A56B-35FE0796C1D3Q38202115-32A03126-D87D-461B-943B-469555F31A59Q38448924-5FB30555-3711-4604-B2F6-140373C61D08Q38777323-370E9518-C0C2-447F-A2BF-CE28229F1E1CQ39209626-3476DC03-F4E2-449A-A9AF-395AED8FDA01Q39733766-B24B454F-30C1-44C6-A2AC-E8F321EF052FQ39847509-3A005787-B1F5-40C2-93F0-FE96466B4935Q41489717-2C88E4E0-16A8-43B9-AEAE-7F19F63994AD
P2860
NO- and haem-independent soluble guanylate cyclase activators.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
NO- and haem-independent soluble guanylate cyclase activators.
@en
NO- and haem-independent soluble guanylate cyclase activators.
@nl
type
label
NO- and haem-independent soluble guanylate cyclase activators.
@en
NO- and haem-independent soluble guanylate cyclase activators.
@nl
prefLabel
NO- and haem-independent soluble guanylate cyclase activators.
@en
NO- and haem-independent soluble guanylate cyclase activators.
@nl
P1476
NO- and haem-independent soluble guanylate cyclase activators.
@en
P2093
Harald H H W Schmidt
Peter M Schmidt
P304
P356
10.1007/978-3-540-68964-5_14
P577
2009-01-01T00:00:00Z